Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 7/20 | 0.56 |
| ▸ | BCHE | P06276 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL803463 | 0.91 | CYP2D6 (0.59) | ACHEBCHEALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL803462 | 0.90 | CCR3 (0.67) | CCR3ACHEBCHEALDH1A1CXCR4 | |
| SCHEMBL28657725 | 0.86 | CCR3 (0.57) | CCR3ACHEBCHEALDH1A1BACE1 | |
| SCHEMBL5969123 | 0.85 | CCR3 (0.64) | CCR3ACHEBCHEALDH1A1BACE1 | |
| SCHEMBL5969122 | 0.85 | CCR3 (0.64) | CCR3ACHEBCHEALDH1A1BACE1 | |
| SCHEMBL13221838 | 0.84 | CCR3 (0.49) | CCR3ACHEBCHEALDH1A1BACE1 | |
| SCHEMBL13107603 | 0.84 | CCR3 (0.49) | CCR3ACHEBCHEALDH1A1BACE1 | |
| SCHEMBL803095 | 0.84 | HSD11B1 (0.47) | CCR3ACHE | |
| SCHEMBL12424946 | 0.83 | CCR3 (0.62) | CCR3ACHEBCHEALDH1A1BACE1 | |
| SCHEMBL22435962 | 0.83 | CCR3 (0.62) | CCR3ACHEBCHEALDH1A1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| WO-2011088045-A1 | AURORA KINASE COMPOUNDS AND METHODS OF THEIR USE | AMBIT BIOSCIENCES CORPORATION (US) | 2011-07-21 | — | — | WO | disclosed |
| US-20100249111-A1 | MULTI-RING COMPOUNDS AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2010-09-30 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249111-A1 | MULTI-RING COMPOUNDS AND USES THEREOF | TP53, BCOR, HPGDS | CCR3 1673/4885ACHE 3481/4885BCHE 2124/4885 |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | HPGDS, HPGD, DPYD | CCR3 2505/4885ACHE 3354/4885BCHE 3384/4885 |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | HPGDS, HPGD, DPYD | CCR3 2505/4885ACHE 3354/4885BCHE 3384/4885 |
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | CCR3 517/4885ACHE 746/4885BCHE 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.